Table 3. IC₅₀ values for palbociclib treatment and mutational profiles of NSCLC cell lines.

			GENETIC STATUS
CELL LINE	HISTOLOGY	PALBOCICLIB IC50 (nM)	p16	RB	CDKN2A	APC	EGFR	KIT	KRAS	HRAS	NRAS	PDGFRA	TP53
H520	SQ	21.6 ± 3.7	-	+	DELETED	WT	WT	WT	WT	WT	WT	WT	MT
H441	AD	62.4 ± 10	-	+	METHYLATED	WT	WT	WT	MT	WT	WT	WT	MT
H358	BAC	87.8 ± 16	-	+	METHYLATED	WT	WT	WT	MT	WT	WT	WT	WT
H1792	AD	100.2 ± 45	-	+	METHYLATED	WT	WT	WT	MT	WT	WT	WT	MT
H2347	NOS	134 ± 22	-	+	METHYLATED	WT	WT	WT	WT	WT	MT	WT	MT
H1299	LCC	283 ± 220	-	+	DELETED	WT	WT	WT	WT	WT	MT	WT	MT
H1650	BAC	730± 240	-	+	DELETED	WT	MT	WT	WT	WT	WT	WT	MT
H125	AD	5421 ± 1606	-	+	DELETED	WT	WT	WT	WT	WT	WT	WT	MT
H1734	NOS	3864 ± 464	+	-	UNMETHYLATED	WT	WT	WT	MT	WT	WT	WT	MT
H2009	AD	4086 ± 384	+	-	UNMETHYLATED	WT	WT	WT	MT	WT	WT	WT	MT

The dashed horizontal lines divide the p16 absent cell lines into different groups based on sensitivity to palbociclib. p16-absent cell lines in the top group are highly sensitive to palbociclib. The cells in the middle group have intermediate sensitivity, and the cell lines in the lower group are considered non-responders. IC₅₀ values are the mean ± SEM of at least three independent experiments, each performed in triplicate. SQ, squamous cell carcinoma; AD, adenocarcinoma; BAC, bronchioalveolar carcinoma (adenocarcinoma-in-situ); NOS, not otherwise specified; LCC, large cell carcinoma; WT, wildtype; MT, mutated.